The Lustgarten Foundation’s flagship clinical research mechanism funds highly collaborative, science-driven clinical studies designed to accelerate the translation of pancreatic cancer research discoveries into patient benefit. Studies supported through the CAI are typically smaller-scale and emphasize deep translational analyses. LOIs are reviewed by Lustgarten’s Translational Advisory Group (TAG); only select applicants are invited to submit full grant applications.
Eligibility Criteria:
Applicants must:
- Hold an M.D., D.M.D., D.V.M., Ph.D., or equivalent degree with a faculty position or equivalent
- Be at a non-profit academic, medical, or research institution (domestic and international eligible)
- Propose collaborative, team-based clinical or translational pancreatic cancer research
- No citizenship requirements
Funding Details:
- Typically $1.5M–$2M total per project (budget determined by scope and scientific merit)
- Duration: Up to 3 years
- Indirect costs capped at 10% of direct costs
Deadline:
- LOI due: May 31, 2026 (via ProposalCentral)
- TAG Presentation invitations: by July 2026
- Full grant application invitations: by September 2026
- Award notification: by January 2027
Where to go for further information:
- Program details.
- Contact: Sejin Chung, Program Scientist — schung@lustgarten.org